Spondyloarthritis & psoriatic arthritis
How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients
Authors' conclusion
PsAID-12 scoring correlates with multiple measures of disease severity and odds of treatment escalation. However, most clinicians reported that the PsAID-12 did not influence treatment escalation decisions.
Study context
- Population
- Patients with PsA in routine care across the UK and Europe, July 2021 to March 2022, whose PsAID-12 results were shared with their physician
- Participants
- 503 patients
- Outcome
- Treatment change and escalation; association of PsAID-12 with escalation
Methodological detailsmulticentre (UK and Europe)
- Multicentre (UK and Europe)
Main finding
As reported in the abstract
Patients with changes made to treatment
36.2%
Of these, treatment escalation
88.8%
Increase in PsAID-12 score and odds of treatment escalation, OR
1.58
P < 0.0001
Observational data: associations, not effects.
Further findings
Physician's assessment of disease activity and treatment escalation
- OR per 1-point score increase (most statistically significant effect)
- 2.68
Other factors associated with treatment escalation
- Escalation more likely in patients not treated with biologic therapies
- Patient characteristics, physician characteristics, disease activity and disease impact associated with escalation
Original publication
How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology (Oxford). Published 8 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →